NMBio’s 2019 kickoff meeting will feature two firms on the verge of breakout success as well as an overview on groundbreaking bioscience research that’s taking place at New Mexico Tech:
VisionQuest has developed and successfully deployed a software product for automatic analysis of retinal images in the detection of lesions in patients with diabetic retinopathy, age-related macular degeneration (AMD), and glaucoma. Its automatic, real-time image quality screening system is also now being used in two commercial retinal cameras to ensure the highest possible retinal image. Speaker: Simon Barriga, Ph.D., CEO
Agilvax is a private company that discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases. Its lead asset is AX09 immunotherapy candidate for the treatment of aggressive forms of breast cancer. Immunization with AX09 elicits antibodies targeting breast cancer stem cells, a key cellular reservoir for relapse, metastatic progression and therapeutic resistance. Speaker: Michael Perrine, MS, MBA, Director of Business Development
Date: January 24
Place: Lobo Rainforest Building
101 Broadway Blvd NE, Albuquerque, NM 87102 (add map location)
Time: Noon
Fee: $20 for NMBio & NMTC members; $35 for non-members